Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,248 GBX | +0.02% | -0.03% | +15.66% |
10:04am | ASTRAZENECA : UBS reiterates its Sell rating | ZD |
May. 14 | FDA extends review of Ascendis Pharma's hormone disorder therapy | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.66% | 239B | |
+32.14% | 588B | |
-3.20% | 364B | |
+19.48% | 326B | |
+5.02% | 285B | |
+10.35% | 210B | |
-7.12% | 200B | |
+8.86% | 167B | |
-0.38% | 161B | |
+1.59% | 124B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Truqap Plus Faslodex Breast Cancer Treatment Bags EU Approval Recommendation